profit from every $100 of sales.
$0$100
Guardian Pharmacy Services
$49.52+0.28% today
+77.4% in 1 year
1-year low $27.031-year high $49.98
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $63.74 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Guardian Pharmacy Services sold, what it kept, and what it did with the cash.
Sales went from $909 million in 2022 to $1.45 billion in 2025, with $49.2 million of profit last year.
SalesProfit
Guardian Pharmacy Services handed back 36% of the cash it generated last year.
Buybacks $29M
Free cash flow 2025$81M
Bought back its own shares$29M
Paid as dividends$0
Cash vs. debt$66M vs. $37M
Guardian Pharmacy Services vs. similar companies
Guardian Pharmacy Services grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Guardian Pharmacy Services | 63.7× · Very expensive | ||
 HCA Healthcare | 15.4× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.9× · Fair price | ||
 IHH Healthcare Berhad | 34.3× · Expensive | ||
 Rede D'Or São Luiz | 16.2× · Fair price |
Compare Guardian Pharmacy Services with CVS Health
AI analysis
An AI analyst reads Guardian Pharmacy Services's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 909 | 1,046 | 1,228 | 1,449 | |
| 186 | 208 | 244 | 293 | |
| 52 | 41 | -63 | 73 | |
| 68 | 59 | -43 | 96 | |
| 35 | 24 | -87 | 49 | |
| 0.58 | 0.00 | -1.77 | 0.78 | |
| 20.4% | 19.9% | 19.9% | 20.2% | |
| 5.7% | 3.9% | -5.1% | 5.0% | |
| 3.9% | 2.3% | -7.1% | 3.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 256 | 271 | 321 | 413 |
| Cash | 1 | 1 | 5 | 66 |
| Total debt | 57 | 61 | 30 | 37 |
| Total liabilities | 180 | 211 | 171 | 195 |
| 0 | 0 | 143 | 206 | |
| 61 | 61 | 62 | 63 | |
| 71.7% | 52.6% | -28.9% | 24.1% | |
| – | – | -61.2% | 23.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 49 | 71 | 58 | 100 | |
| 17 | 15 | 16 | 20 | |
| 32 | 56 | 42 | 81 | |
| Dividends paid | 31 | 38 | 36 | 0 |
| – | 0 | 55 | 29 | |
| -3 | -6 | 131 | 14 |
Valuation
- 63.7×
- 40.4×
- 6.22
- 15.2×
- 2.2×
- 38.9×
- 32.2×
- 2.6%
- 1.6%
- 0.0%
Profitability
- 20.2%
- 5.0%
- 3.4%
- 7.3%
- 24.7%
- 30.6%
- 27.2%
- 12.4%
- 31.4%
- –
Growth
- +16.8%
- +10.2%
- +94.1%
- –
- +1.3%
Financial health
- -0.3×
- 0.18
- 8.6%
- 111.4×
- 1.38
- 1.17
- 3.41
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 5%of 946
Bottom 39%of 872
Bottom 16%of 563
Top 34%of 868
Top 38%of 986
What analysts expect
- Average price target
- $38.00
- Range
- $36.00 – $40.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.29 | 0.24 | +20.8% |
| Mar 11, 2026 | 0.37 | 0.27 | +37.0% |
| Nov 10, 2025 | 0.25 | 0.24 | +4.2% |
| Aug 11, 2025 | 0.23 | 0.22 | +4.5% |
| May 12, 2025 | 0.21 | 0.22 | −4.5% |
| Mar 26, 2025 | 0.24 | 0.21 | +14.3% |
| Nov 12, 2024 | -2.00 | 0.19 | −1,152.6% |
| Sep 26, 2024 | 0.17 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
61Pass
Benjamin Graham
24No pass
Philip Fisher
43No pass
Peter Lynch
37No pass
Joel Greenblatt
24No pass
Charlie Munger
51No pass
Terry Smith
56No pass
Questions about Guardian Pharmacy Services
Is Guardian Pharmacy Services a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Guardian Pharmacy Services AI analysis
What does Guardian Pharmacy Services do?
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. It is in Medical Care Facilities, based in Atlanta, GA, United States, with 3,600 employees.
Does Guardian Pharmacy Services pay a dividend?
No. Guardian Pharmacy Services does not pay a dividend at the moment; in 2025 it returned $29.0 million to shareholders by buying back its own shares.
Is Guardian Pharmacy Services stock halal?
Yes. Guardian Pharmacy Services passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Guardian Pharmacy Services stock done over the past year?
Up 77.4% over the past twelve months, to $49.52. It traded between $27.03 and $49.98, close to its high.
Who are Guardian Pharmacy Services's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with Guardian Pharmacy Services's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.